Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB (GEN)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 09/21 10:06:32 am
1053 DKK   +0.43%
09/19GENMAB : to Host Capital Markets Day
AQ
09/18Capital Increase in Genmab as a Result of Employee Warrant Exerci..
GL
09/18GENMAB : Admission of new securities
CO
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
1062.5(c) 1044.5(c) 1017(c) 1048.5(c) 1055 Last
123 809 141 844 213 539 174 402 33 875 Volume
-2.57% -1.69% -2.63% +3.10% +0.62% Change
More quotes
Financials (DKK)
Sales 2018 2 993 M
EBIT 2018 1 477 M
Net income 2018 1 373 M
Finance 2018 5 879 M
Yield 2018 -
Sales 2019 4 275 M
EBIT 2019 2 561 M
Net income 2019 2 245 M
Finance 2019 7 910 M
Yield 2019 -
P/E ratio 2018 46,92
P/E ratio 2019 28,91
EV / Sales2018 19,6x
EV / Sales2019 13,2x
Capitalization 64 453 M
More Financials
Company
Genmab A/S operates as an international biotechnology company.The firm develops human antibody therapeutics for the treatment of cancer.Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX.The company was founded by Donald Lee Drakeman,... 
Sector
Biotechnology & Medical Research
Calendar
09/26 | 02:00pmCapital Markets Day
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
09/19GENMAB : to Host Capital Markets Day
AQ
09/18Capital Increase in Genmab as a Result of Employee Warrant Exercise
GL
09/18GENMAB : Admission of new securities
CO
09/10GENMAB : to Present at Morgan Stanley 16th Annual Global Healthcare Conference
AQ
09/06GENMAB : to Present at Morgan Stanley 16th Annual Global Healthcare Conference
AQ
09/03GENMAB : Announces European Marketing Authorization for DARZALEX for Front Line ..
AQ
08/31GENMAB : Announces European Marketing Authorization for DARZALEX® (daratumumab) ..
AQ
08/20GENMAB A/S : has published its Articles of Association
AQ
08/14GENMAB : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
08/14GENMAB : Announces Financial Results for the First Half of 2018
AQ
More news
Sector news : Bio Therapeutic Drugs
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/10The newly minted CMO is better known for the six years she spent at Genmab. I..
1
09/03$GEN A/S Genmab: Expected European approval in 1L MM for Darzalex: Brief Com.. 
08/14#Frankfurt #stocks: Genmab : #Acquisition Concluded shallow sales profits in.. 
08/13Jefferies Financial Group Lowers Genmab A/S Q3 2018 Earnings Estimates to $0... 
08/09Genmab reports Q2 results  
More tweets
Qtime:32
News from SeekingAlpha
08/31Darzalex combo therapy OK'd in Europe for first-line multiple myeloma 
08/11Genmab A/S (GNMSF) CEO Jan van de Winkel on Q2 2018 Results - Earnings Call T.. 
08/09Genmab A/S 2018 Q2 - Results - Earnings Call Slides 
08/09Genmab reports Q2 results 
07/303 THINGS IN BIOTECH, JULY 30 : Europe News Continues To Dominate 
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 1 331  DKK
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman
Pernille Lyngvold Erenbjerg Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB1.90%10 184
GILEAD SCIENCES4.45%95 774
VERTEX PHARMACEUTICALS17.84%45 132
REGENERON PHARMACEUTICALS2.06%40 728
NEUROCRINE BIOSCIENCES, INC.51.32%10 622
SAREPTA THERAPEUTICS INC174.68%10 096